Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-03-04

Clinical Trial Update: A Controlled Trial of Erenumab in Migraine Prevention [Phase 3]

View source ↗

Summary

Phase 3 trial results for erenumab in migraine prevention have completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • erenumab (erenumab)

Snippet

Sponsor: Amgen | Conditions: Migraine | Phase 3 | Status: COMPLETED | Results posted: 2021-03-04